Literature DB >> 30962285

HDAC5 catalytic activity suppresses cardiomyocyte oxidative stress and NRF2 target gene expression.

Tianjing Hu1, Friederike C Schreiter2,3, Rushita A Bagchi1, Philip D Tatman4, Mark Hannink5, Timothy A McKinsey6.   

Abstract

Histone deacetylase 5 (HDAC5) and HDAC9 are class IIa HDACs that function as signal-responsive repressors of the epigenetic program for pathological cardiomyocyte hypertrophy. The conserved deacetylase domains of HDAC5 and HDAC9 are not required for inhibition of cardiac hypertrophy. Thus, the biological function of class IIa HDAC catalytic activity in the heart remains unknown. Here we demonstrate that catalytic activity of HDAC5, but not HDAC9, suppresses mitochondrial reactive oxygen species generation and subsequent induction of NF-E2-related factor 2 (NRF2)-dependent antioxidant gene expression in cardiomyocytes. Treatment of cardiomyocytes with TMP195 or TMP269, which are selective class IIa HDAC inhibitors, or shRNA-mediated knockdown of HDAC5 but not HDAC9 leads to stimulation of NRF2-mediated transcription in a reactive oxygen species-dependent manner. Conversely, ectopic expression of catalytically active HDAC5 decreases cardiomyocyte oxidative stress and represses NRF2 activation. These findings establish a role of the catalytic domain of HDAC5 in the control of cardiomyocyte redox homeostasis and define TMP195 and TMP269 as a novel class of NRF2 activators that function by suppressing the enzymatic activity of an epigenetic regulator.
© 2019 Hu et al.

Entities:  

Keywords:  NRF2; cardiac hypertrophy; cardiomyocyte; histone deacetylase; histone deacetylase (HDAC); mitochondria; nuclear factor 2 (erythroid-derived 2–like factor, NFE2L2, Nrf2); oxidative stress

Mesh:

Substances:

Year:  2019        PMID: 30962285      PMCID: PMC6544848          DOI: 10.1074/jbc.RA118.007006

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  41 in total

Review 1.  Cardiac plasticity.

Authors:  Joseph A Hill; Eric N Olson
Journal:  N Engl J Med       Date:  2008-03-27       Impact factor: 91.245

2.  Developing New Treatments for Heart Failure: Focus on the Heart.

Authors:  Mihai Gheorghiade; Christopher J Larson; Sanjiv J Shah; Stephen J Greene; John G F Cleland; Wilson S Colucci; Preston Dunnmon; Stephen E Epstein; Raymond J Kim; Ramin V Parsey; Norman Stockbridge; James Carr; Wilfried Dinh; Thomas Krahn; Frank Kramer; Karin Wahlander; Lawrence I Deckelbaum; David Crandall; Shunichiro Okada; Michele Senni; Sergey Sikora; Hani N Sabbah; Javed Butler
Journal:  Circ Heart Fail       Date:  2016-05       Impact factor: 8.790

3.  Promiscuous actions of small molecule inhibitors of the protein kinase D-class IIa HDAC axis in striated muscle.

Authors:  Douglas D Lemon; Brooke C Harrison; Todd R Horn; Matthew S Stratton; Bradley S Ferguson; Michael F Wempe; Timothy A McKinsey
Journal:  FEBS Lett       Date:  2015-03-25       Impact factor: 4.124

4.  Cardiac HDAC6 catalytic activity is induced in response to chronic hypertension.

Authors:  Douglas D Lemon; Todd R Horn; Maria A Cavasin; Mark Y Jeong; Kurt W Haubold; Carlin S Long; David C Irwin; Sylvia A McCune; Eunhee Chung; Leslie A Leinwand; Timothy A McKinsey
Journal:  J Mol Cell Cardiol       Date:  2011-04-23       Impact factor: 5.000

5.  Nrf2 protects against maladaptive cardiac responses to hemodynamic stress.

Authors:  Jinqing Li; Tomonaga Ichikawa; Luis Villacorta; Joseph S Janicki; Gregory L Brower; Masayuki Yamamoto; Taixing Cui
Journal:  Arterioscler Thromb Vasc Biol       Date:  2009-07-10       Impact factor: 8.311

6.  Chemical phylogenetics of histone deacetylases.

Authors:  James E Bradner; Nathan West; Melissa L Grachan; Edward F Greenberg; Stephen J Haggarty; Tandy Warnow; Ralph Mazitschek
Journal:  Nat Chem Biol       Date:  2010-02-07       Impact factor: 15.040

7.  Prevention by sulforaphane of diabetic cardiomyopathy is associated with up-regulation of Nrf2 expression and transcription activation.

Authors:  Yang Bai; Wenpeng Cui; Ying Xin; Xiao Miao; Michelle T Barati; Chi Zhang; Qiang Chen; Yi Tan; Taixing Cui; Yang Zheng; Lu Cai
Journal:  J Mol Cell Cardiol       Date:  2013-01-23       Impact factor: 5.000

8.  A redox-dependent pathway for regulating class II HDACs and cardiac hypertrophy.

Authors:  Tetsuro Ago; Tong Liu; Peiyong Zhai; Wei Chen; Hong Li; Jeffery D Molkentin; Stephen F Vatner; Junichi Sadoshima
Journal:  Cell       Date:  2008-06-13       Impact factor: 41.582

9.  Prognostic significance of left ventricular mass change during treatment of hypertension.

Authors:  Richard B Devereux; Kristian Wachtell; Eva Gerdts; Kurt Boman; Markku S Nieminen; Vasilios Papademetriou; Jens Rokkedal; Katherine Harris; Peter Aurup; Björn Dahlöf
Journal:  JAMA       Date:  2004-11-17       Impact factor: 56.272

10.  ConsensusPathDB: toward a more complete picture of cell biology.

Authors:  Atanas Kamburov; Konstantin Pentchev; Hanna Galicka; Christoph Wierling; Hans Lehrach; Ralf Herwig
Journal:  Nucleic Acids Res       Date:  2010-11-11       Impact factor: 16.971

View more
  11 in total

Review 1.  Redox signaling, mitochondrial metabolism, epigenetics and redox active phytochemicals.

Authors:  Renyi Wu; Shanyi Li; Rasika Hudlikar; Lujing Wang; Ahmad Shannar; Rebecca Peter; Pochung Jordan Chou; Hsiao-Chen Dina Kuo; Zhigang Liu; Ah-Ng Kong
Journal:  Free Radic Biol Med       Date:  2020-12-24       Impact factor: 7.376

Review 2.  Nanophytomedicines for the Prevention of Metabolic Syndrome: A Pharmacological and Biopharmaceutical Review.

Authors:  Zeinab Nouri; Marziyeh Hajialyani; Zhila Izadi; Roodabeh Bahramsoltani; Mohammad Hosein Farzaei; Mohammad Abdollahi
Journal:  Front Bioeng Biotechnol       Date:  2020-05-14

Review 3.  Exercise, redox homeostasis and the epigenetic landscape.

Authors:  Ivan Dimauro; Maria Paola Paronetto; Daniela Caporossi
Journal:  Redox Biol       Date:  2020-02-26       Impact factor: 11.799

4.  EGCG prevents pressure overload‑induced myocardial remodeling by downregulating overexpression of HDAC5 in mice.

Authors:  Xiao Han; Chang Peng; Lixin Huang; Xiaomei Luo; Qian Mao; Shuqi Wu; Huanting Zhang
Journal:  Int J Mol Med       Date:  2021-11-29       Impact factor: 4.101

Review 5.  Epigenetics/Epigenomics and Prevention of Early Stages of Cancer by Isothiocyanates.

Authors:  Rasika Hudlikar; Lujing Wang; Renyi Wu; Shanyi Li; Rebecca Peter; Ahmad Shannar; Pochung Jordan Chou; Xia Liu; Zhigang Liu; Hsiao-Chen Dina Kuo; Ah-Ng Kong
Journal:  Cancer Prev Res (Phila)       Date:  2020-10-14

6.  Nrf2 Activator PB125® as a Potential Therapeutic Agent against COVID-19.

Authors:  Joe M McCord; Brooks M Hybertson; Adela Cota-Gomez; Kara P Geraci; Bifeng Gao
Journal:  Antioxidants (Basel)       Date:  2020-06-12

Review 7.  Roles of Histone Acetylation Modifiers and Other Epigenetic Regulators in Vascular Calcification.

Authors:  Duk-Hwa Kwon; Juhee Ryu; Young-Kook Kim; Hyun Kook
Journal:  Int J Mol Sci       Date:  2020-05-04       Impact factor: 5.923

8.  The Selective Class IIa Histone Deacetylase Inhibitor TMP195 Resensitizes ABCB1- and ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Cytotoxic Anticancer Drugs.

Authors:  Chung-Pu Wu; Sabrina Lusvarghi; Jyun-Cheng Wang; Sung-Han Hsiao; Yang-Hui Huang; Tai-Ho Hung; Suresh V Ambudkar
Journal:  Int J Mol Sci       Date:  2019-12-29       Impact factor: 5.923

Review 9.  The Roles of Histone Deacetylases and Their Inhibitors in Cancer Therapy.

Authors:  Guo Li; Yuan Tian; Wei-Guo Zhu
Journal:  Front Cell Dev Biol       Date:  2020-09-29

10.  Histone Deacetylase Inhibitor Suberoylanilide Hydroxamic Acid Improves Energetic Status and Cardiomyogenic Differentiation of Human Dilated Myocardium-Derived Primary Mesenchymal Cells.

Authors:  Rokas Miksiunas; Kestutis Rucinskas; Vilius Janusauskas; Siegfried Labeit; Daiva Bironaite
Journal:  Int J Mol Sci       Date:  2020-07-08       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.